Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Commercial Sponsor
Exelixis
Scientific Title
A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination With Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects With Metastatic Castration-Resistant Prostate Cancer